Global Gastrointestinal Drugs Market Research Report Forecast to 2023

Report / Search Code: MRFR/Pharma/0115-HCRR
Publish Date: 15 May, 2019

Description:

Global Gastrointestinal Drugs Market Research Report, by Drug Category (Acid Neutralizers, Laxatives and Antidiarrheal, Anti-inflammatory drugs, Antiemetic), By Route of Administration (Oral, Parenteral, Rectal), By Disease Type (Gastroesophageal Reflux Disease, Inflammatory Bowel Disease), By end user (Hospital Pharmacies, Retail Pharmacies) - Forecast till 2023

Market Scenario:
Gastrointestinal (GI) diseases affects stomach, large intestine and rectum, small intestine, esophagus, liver, gallbladder and pancreas. The symptoms of GI diseases are heartburn, indigestion, bloating, constipation and many more. According to a report by the World Gastroenterology Organization, 35-40 % of world’s total population is suffering from acute or chronic GI complication. Increasing patient having GI diseases and disorders, due to change in dietary pattern are the major factor for increasing the global GI drug market. The exact cause for inflammatory bowel disease and Irritable bowel syndrome are still unknown due to which permanent cure for this disease is not available which may restrain the growth of the market. The global gastrointestinal drug market is expected to grow at CAGR of 4.8% during forecasted period 2017- 2023. It is estimated to reach till USD $ 59.3 Billion by end of 2023.

Study Objectives Global Gastrointestinal Drugs Market Research Report

- To provide thorough understanding of various segment and sub segments of the market.
- Detail Analysis of the various regulatory rules on the growth of market.
- To provide the detail overview of parent market.
- To provide the detail information about drivers and restrain of the market.
- To provide competitive landscape and key players in the market.
- To analyze the market based on various factors- price analysis, supply chain analysis, porters five force analysis etc.
- To provide detail trends and opportunities for the market.
- To provide historical and forecast revenue of the market segments and sub-segments with respect to four main geographies and their countries- North America, Europe, Asia Pacific and Middle East and Africa.
- To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the global gastrointestinal drugs Market.

Figure 1- Global Gastrointestinal Drugs Market Share, by region
Key Players for Global Gastrointestinal Drugs market
AbbVie Inc. (US), AstraZeneca (UK), Johnson & Johnson (US), Valeant (US), Abbott Laboratories (US), Allergan Plc (US), Bayer AG (Germany), Janssen Biotech Inc. (US), Takeda Pharmaceutical Company Limited (Japan), Eisai Co., Ltd. (Japan), Valeant Pharmaceuticals (US), Sanofi (France), Janssen Biotech (US), GlaxoSmithKline Plc. (UK), Boehringer Ingelheim GmbH (Germany).

Segmentation
Global Gastrointestinal Drugs market has been segmented on the basis of Drug Category they are segmented into Acid Neutralizers, Laxatives and Antidiarrheal, antiemetic, Anti-inflammatory drugs and other. By Route of Administration they are segmented into Oral, Parenteral and rectal. By disease Type they are Gastroesophageal Reflux Disease, Inflammatory Bowel Disease and Other. And by End User Hospital Pharmacies, Retail Pharmacies and Other.

Acid Neutralizers which are further sub segmented into Antacids, H2 antagonists, Proton pump inhibitors and Others,

Research Methodology

Regional Analysis
North America, Europe, Asia Pacific and Middle East and Africa are the four major regional segment of global GI drugs market. North America account for the largest market share for the global gastrointestinal drug market. Increasing geriatric population is the major driving factor for the market of GI drugs in North America. Europe and Asia Pacific share nearly similar amount of market. Introduction of new drugs and different technology has increased the market in Asia Pacific and Europe. Asia Pacific is the most favourable region for the development of GI drug market. Huge
population and infrastructural improvement has increases the scope for the development of this market in coming future.

The report for Global Gastrointestinal Drugs Market Research Report of Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and industry performance. The report gives the clear picture of current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides details information and strategies of the top key players in the industry. The report also gives a broad study of the different markets segments and regions.

Intended Audience

- Manufacturing industries.
- Pharmaceutical industry.
- Biotechnology Companies
- Research and Development (R&D) Companies
5.2 LAXATIVES AND ANTIARRHEAL
5.3 ANTIEMETIC
5.4 ANTI-INFLAMMATORY DRUGS
5.5 OTHER

6. GLOBAL GASTROINTESTINAL DRUGS MARKET, BY ROUTE OF ADMINISTRATION
6.1 ORAL
6.2 PARENTERAL
6.3 RECTAL

7. GLOBAL GASTROINTESTINAL DRUGS MARKET, DISEASE TYPE
7.1 GASTROESOPHAGEAL REFLUX DISEASE
7.2 INFLAMMATORY BOWEL DISEASE
7.3 OTHER

8. GLOBAL GASTROINTESTINAL DRUGS MARKET
8.1 HOSPITAL PHARMACIES
8.2 RETAIL PHARMACIES
8.3 OTHER

9. GLOBAL GASTROINTESTINAL DRUGS MARKET, BY REGION
9.1 INTRODUCTION
9.2 NORTH AMERICA
9.2.1 US
9.2.2 CANADA
9.3 EUROPE
9.3.1 WESTERN EUROPE
9.3.1.1 GERMANY
9.3.1.2 FRANCE
9.3.1.3 ITALY
9.3.1.4 SPAIN
9.3.1.5 UK
9.3.1.6 REST OF WESTERN EUROPE
9.3.2 EASTERN EUROPE
9.4 ASIA
9.4.1 JAPAN
9.4.2 CHINA
9.4.3 INDIA
9.4.4 AUSTRALIA
9.4.5 REPUBLIC OF KOREA
9.5 REST OF ASIA-PACIFIC
9.6 MIDDLE EAST & AFRICA

10. COMPETITIVE LANDSCAPE
10.1 MAJOR STRATEGIES ADOPTED BY MARKET PLAYERS
10.1.1 STRATEGIC PARTNERSHIP
10.1.2 MERGER & ACQUISITION

11 COMPANY PROFILE
11.1 ABBVIE INC.
11.1.1 OVERVIEW
11.1.2 PRODUCT OVERVIEW
11.1.3 FINANCIALS
11.1.4 KEY DEVELOPMENTS
11.2 ASTRAZENECA
11.2.1 OVERVIEW
11.2.2 PRODUCT OVERVIEW
11.2.3 FINANCIALS
11.2.4 KEY DEVELOPMENTS
11.3 JOHNSON & JOHNSON
11.3.1 OVERVIEW
11.3.2 PRODUCT OVERVIEW
11.3.3 FINANCIALS
11.3.4 STRATEGY
11.3.5 KEY DEVELOPMENT
11.4 VALEANT
11.4.1 OVERVIEW
11.4.2 PRODUCT OVERVIEW
11.4.3 FINANCIALS
11.4.4 KEY DEVELOPMENTS
11.5 ALLERGAN PLC
11.5.1 OVERVIEW
11.5.2 PRODUCT OVERVIEW
11.5.3 FINANCIALS
11.5.4 KEY DEVELOPMENTS
11.6 OTHERS